ERLANGEN, Germany--(BUSINESS WIRE)--An evaluation has revealed positive intermediate results for the first three months of data from the clinical trials for the treatment of therapy resistant epilepsies with the world’s first device using transcutaneous vagus nerve stimulation (t-VNS®), from cerbomed gmbh. t-VNS® proves its good safety profile and scores high on user-friendliness, and there are also preliminary indications of its effectiveness, for the patients in the cMPsE01 pilot study.